Garo Armen, Agenus CEO (Wikimedia Commons)
Spurned by FDA on another immunotherapy, Agenus holds up early data for CTLA-4 drug across tumor types
In a Phase I study across nine tumor types, Agenus’ CTLA-4 drug AGN1181 posted one complete response and three partial responses as a monotherapy, offering …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
